01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#VELA investee co. #ENSI Ensilica PLC – US$7m e-mobility sensor ASIC supply contract win September 13, 2023 – Posted in: Blog, Vela Technologies Plc (VELA)

EnSilica, a leading chip maker of mixed signal ASICs (Application Specific Integrated Circuits), is pleased to announce that it has been awarded an ASIC supply contract for a sensor ASIC to address the e-mobility market (the “Contract“). The Contract is for the design and supply of a mixed signal sensor ASIC for the e-mobility market encompassing electric vehicles (EVs), electric two wheelers, e-bikes, and e-scooters. Based on the volume commitments by the customer, the Contract…

Continue reading

#ORPH Open Orphan – £10.4m contract with existing Big Pharma client August 22, 2022 – Posted in: Blog, Open Orphan (ORPH)

hVIVO to develop new influenza challenge strain to test oral antiviral candidate   Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces thathVIVO, a subsidiary of Open Orphan, has signed a £10.4m contract with an existing top 5 global pharmaceutical client to manufacture a new batch of H1N1 influenza challenge virus, leveraging off an existing in-house…

Continue reading

#POLB Poolbeg Pharma – GMP manufacturing contract signed May 12, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)

Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces an update on its lead asset, POLB 001, a small molecule immunomodulator which aims to address a significant unmet need in severe influenza. The Company has signed a contract for GMP manufacturing, ensuring ample supply of GMP grade POLB 001 for use in its upcoming LPS human challenge clinical trial, due…

Continue reading